CTOs on the Move

Horizon Therapeutics

www.horizontherapeutics.com

 
At Horizon Therapeutics, we believe science and compassion must work together to transform lives. We are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. For us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Spokane Inter Res Tech Ins

Spokane Inter Res Tech Ins is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FosunPharmaUSA

NOW AVAILABLETobramycin for Injections, USPOur ProductsCovid-19 Detection Kit and Extraction ReagentLearn MoreSpecialty Pharmaceutical Injectables & Ophthalmics Our ProductsIn The NewsFosun Partners with The National Children’s Cancer SocietyLearn More...

AbbVie Canada

We`re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people`s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company. Our ~30,000 employees are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe. We come up with new approaches to addressing today`s health issues—from life-threatening illness to chronic conditions. We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We`re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients` lives, on societies—and on science itself. At AbbVie, we see a future full of possibility, where health is in reach and patient lives are improved. See our employees, our science and our hope for tomorrow: Our purpose is profound, and our path is clear. We embrace the responsibility of making a remarkable impact on people`s lives through the innovative medicines and solutions we create together. This is driven by our compassion for people, commitment to innovation and inclusion, service to the community, and uncompromising integrity at the heart of everything we do. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world. Globally, our employees embrace diverse backgrounds and perspectives and treat everyone equally, with dignity and respect, allowing us all to achieve our best. We proudly do our part to serve and support our communities and protect the environment, making a lasting impact that`s felt within healthcare and beyond. What we do isn`t easy, but we persevere because what we achieve inspires hope and transforms lives—every single day.

WCG IRB

WCG is the world`s leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two divisions, the industry`s first central IRB – WCG IRB – and first clinical services organization, WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection.

Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company`s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.